Dmitry I. Trukhan , Anatoly F. Sulimov , Larisa Yu. Trukhan , Innokenty S. Chusov , Igor N. Stepanov
Abstract
Doctors of various specialties face orofacial pain in their practice: dentists, maxillofacial surgeons, neurologists, otorhinolaryngologists, therapists, traumatologists, ophthalmologists, psychotherapists, physiotherapists, aesthetic medicine doctors, neurosurgeons, anesthesiologists, plastic surgeons and other specialists. The novel coronavirus infection (COVID-19) pandemic, spread by the SARS-CoV-2 virus, has become a challenge for all medical specialties and health care systems around the world. We searched the literature for the period from the beginning of the pandemic until June 15, 2022, on the study of the association of orofacial pain with a new coronavirus infection COVID-19 in the electronic search engines PubMed and Scopus. An analysis of the sources found indicates an increase in the frequency of various types of orofacial pain during the COVID-19 pandemic, which is due both to the SARS-CoV-2 infection itself and to a complex of biopsychosocial factors directly related to the pandemic. A number of used drugs, primarily non-steroidal anti-inflammatory drugs, can cause a number of side effects that complicate both dental treatment and negatively affect concomitant comorbid pathology. In this regard, the issues of drug safety and pharmacological "correction" of side effects – protective or protector therapy – become relevant. The use of the universal gastro- and enteroprotector rebamipide is especially important during the pandemic of a new coronavirus infection (COVID-19).
Key words: orofacial pain, novel coronavirus infection (COVID-19), biopsychosocial factors, temporomandibular disorders, bruxism, headache, oral cavity, dentoalveolar structures, cranial nerves, drug safety, proton pump inhibitors, adverse events, rebamipide.
About the Author
Dmitry I. Trukhan 1 , Anatoly F. Sulimov 1 , Larisa Yu. Trukhan 1 , Innokenty S. Chusov 2 , Igor N. Stepanov 11 Omsk State Medical University, Omsk, Russia
2 Budgetary Health Care Institution of the Omsk region City Clinical Perinatal Center, Omsk, Russia
References
1. Международная классификация орофациальной боли, 1-е издание (ICOP). Адаптированная русскоязычная версия. Альманах клинической медицины. 2022; S: 3–80. DOI: 10.18786/2072-0505-2022-50-005
[Mezhdunarodnaia klassifikatsiia orofatsial'noi boli, 1-e izdanie (ICOP). Adaptirovannaia russkoiazychnaia versiia. Al'manakh klinicheskoi meditsiny. 2022; S: 3–80. DOI: 10.18786/2072-0505-2022-50-005 (in Russian).]
2. Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630
[Grinevich V.B., Gubonina I.V., Doshchitsin V.L. et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630 (in Russian).]
3. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации Минздрава России. 15-я версия от 22.02.2022 г. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/ 392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf
[Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Vremennye metodicheskie rekomendatsii Minzdrava Rossii. 15-ia versiia ot 22.02.2022 g. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/VMR_COVID-19_V15.pdf (in Russian).]
4. Casillas Santana MA, Arreguín Cano JA, Dib Kanán A et al. Should We Be Concerned about the Association of Diabetes Mellitus and Periodontal Disease in the Risk of Infection by SARS-CoV-2? A Systematic Review and Hypothesis. Medicina (Kaunas) 2021; 57 (5): 493. DOI: 10.3390/medicina57050493
5. Silvestre FJ, Márquez-Arrico CF. COVID-19 and Periodontitis: A Dangerous Association? Front Pharmacol 2022; 12: 789681. DOI: 10.3389/fphar.2021.789681
6. Jafer MA, Hazazi MA, Mashi MH et al. COVID-19 and Periodontitis: A Reality to Live with. J Contemp Dent Pract 2020; 21 (12): 1398–403. URL: https://pubmed.ncbi.nlm.nih.gov/33893266/#affiliation-1
7. Campisi G, Bizzoca ME, Lo Muzio L. COVID-19 and periodontitis: reflecting on a possible association. Head Face Med 2021; 17 (1): 16. DOI: 10.1186/s13005-021-00267-1
8. Kusiak A, Cichońska D, Tubaja M et al. COVID-19 manifestation in the oral cavity – a narrative literature review. Acta Otorhinolaryngol Ital 2021; 41 (5): 395–400. DOI: 10.14639/0392-100X-N1584
9. Basso L, Chacun D, Sy K et al. Periodontal Diseases and COVID-19: A Scoping Review. Eur J Dent 2021; 15 (4): 768–75. DOI: 10.1055/s-0041-1729139
10. Grigoriadis A, Räisänen IT, Pärnänen P et al. Is There a Link between COVID-19 and Periodontal Disease? A Narrative Review. Eur J Dent 2022. DOI: 10.1055/s-0041-1740223
11. Brock M, Bahammam S, Sima C. The Relationships Among Periodontitis, Pneumonia and COVID-19. Front Oral Health 2022; 2: 801815. DOI: 10.3389/froh.2021.801815
12. Qi X, Northridge ME, Hu M, Wu B. Oral health conditions and COVID-19: A systematic review and meta-analysis of the current evidence. Aging Health Res 2022; 2 (1): 100064. DOI: 10.1016/j.ahr.2022.100064
13. Biadsee A, Biadsee A, Kassem F et al. Olfactory and Oral Manifestations of COVID-19: Sex-Related Symptoms-A Potential Pathway to Early Diagnosis. Otolaryngol Head Neck Surg 2020; 163 (4): 722–8. DOI: 10.1177/0194599820934380
14. Dar-Odeh N, Bobamuratova DT, Alnazzawi A et al. Jaw-related complications in COVID-19 patients; a systematic review. Cranio 2022: 1–8. DOI: 10.1080/08869634.2022.2031438
15. Saccomanno S, Bernabei M, Scoppa F et al. Coronavirus Lockdown as a Major Life Stressor: Does It Affect TMD Symptoms? Int J Environ Res Public Health 2020; 17 (23): 8907. DOI: 10.3390/ijerph17238907
16. Manfredini D, Marini M, Pavan C et al. Psychosocial profiles of painful TMD patients. J Oral Rehabil 2009; 36 (3): 193–8. DOI: 10.1111/j.1365-2842.2008.01926.x
17. Manfredini D, Lombardo L, Siciliani G. Temporomandibular disorders and dental occlusion. A systematic review of association studies: end of an era? J Oral Rehabil 2017; 44 (11): 908–23. DOI: 10.1111/joor.12531
18. De La Torre Canales G, Câmara-Souza MB, Muñoz Lora VR et al. Prevalence of psychosocial impairment in temporomandibular disorder patients: a systematic review. J Oral Rehabil 2018; 45 (11): 881–9. DOI: 10.1111/joor.12685
19. Kindler S, Samietz S, Houshmand M et al. Depressive and anxiety symptoms as risk factors for temporomandibular joint pain: a prospective cohort study in the general population. J Pain 2012; 13 (12): 1188–97. DOI: 10.1016/j.jpain.2012.09.004
20. Boscato N, Almeida RC, Koller CD et al. Influence of anxiety on temporomandibular disorders: an epidemiological survey with elders and adults in Southern Brazil. J Oral Rehabil 2013; 40 (9): 643–9. DOI: 10.1111/joor.12076
21. Osiewicz M, Lobbezoo F, Ciapała B et al. Pain predictors in a population of temporomandibular disorders patients. J Clin Med 2020; 9 (2): 452. DOI: 10.3390/jcm9020452
22. Almeida-Leite CM, Stuginski-Barbosa J, Conti PCR. How psychosocial and economic impacts of COVID-19 pandemic can interfere on bruxism and temporomandibular disorders? J Appl Oral Sci 2020; 28: e20200263. DOI: 10.1590/1678-7757-2020-0263
23. Quadri MF, Mahnashi A, Al Almutahhir A et al. Association of awake bruxism with khat, coffee, tobacco, and stress among Jazan University Students. Int J Dent 2015; 2015: 842096. DOI: 10.1155/ 2015/842096
24. Smardz J, Martynowicz H, Wojakowska A et al. Correlation between sleep bruxism, stress, and depression-A polysomnographic study. J Clin Med 2019; 8 (9): 1344. DOI: 10.3390/jcm8091344
25. Smardz J, Martynowicz H, Michalek-Zrabkowska M et al. Sleep bruxism and occurrence of temporomandibular disorders-related pain: a polysomnographic study. Front Neurol 2019; 10: 168. DOI: 10.3389/ fneur.2019.0016
26. Polmann H, Domingos FL, Melo G et al. Association between sleep bruxism and anxiety symptoms in adults: a systematic review. J Oral Rehabil 2019; 46 (5): 482 91. DOI: 10.1111/joor.12785
27. Przystańska A, Jasielska A, Ziarko M et al. Psychosocial predictors of bruxism. Biomed Res Int 2019; 2019: 2069716. DOI: 10.1155/2019/2069716
28. Wieckiewicz M, Smardz J, Martynowicz H et al. Distribution of temporomandibular disorders among sleep bruxers and non-bruxers: a polysomnographic study. J Oral Rehabil 2020; 10.1111/joor.12955. DOI: 10.1111/joor.1295
29. Saccomanno S, Bernabei M, Scoppa F et al. Coronavirus Lockdown as a Major Life Stressor: Does It Affect TMD Symptoms? Int J Environ Res Public Health 2020; 17 (23): 8907. DOI: 10.3390/ijerph17238907
30. Machoň V, Levorová J, Beňo M, Foltán R. The Manifestations of Covid-19 Infection. Manifestations in Patients with Temporomandibular Joint Disorders. Prague Med Rep 2022; 123 (2): 95–100. DOI: 10.14712/23362936.2022.10
31. DE Caxias FP, Athayde FRF, Januzzi MS et al. Impact event and orofacial pain amid the COVID-19 pandemic in Brazil: a cross-sectional epidemiological study. J Appl Oral Sci 2021; 29: e20210122. DOI: 10.1590/1678-7757-2021-0122
32. Badrah M, Riad A, Kassem I et al. Craniofacial pain in COVID-19 patients with diabetes mellitus: Clinical and laboratory description of 21 cases. J Med Virol 2021; 93 (5): 2616–9. DOI: 10.1002/jmv.26866
33. Asquini G, Bianchi AE, Borromeo G et al. The impact of COVID-19-related distress on general health, oral behaviour, psychosocial features, disability and pain intensity in a cohort of Italian patients with temporomandibular disorders. PLoS One 2021; 16 (2): e0245999. DOI: 10.1371/journal.pone.0245999
34. Saki M, Shadmanpour M, Najafi HZ. Are individuals with orofacial pain more prone to psychological distress during the COVID-19 pandemic? Dent Med Probl 2021; 58 (1): 17–25. DOI: 10.17219/dmp/ 131683
35. Emodi-Perlman A, Eli I. One year into the COVID-19 pandemic – temporomandibular disorders and bruxism: What we have learned and what we can do to improve our manner of treatment. Dent Med Probl 2021; 58 (2): 215–8. DOI: 10.17219/dmp/132896
36. Colonna A, Guarda-Nardini L, Ferrari M, Manfredini D. COVID-19 pandemic and the psyche, bruxism, temporomandibular disorders triangle. Cranio 2021; Oct 15: 1–6. DOI: 10.1080/08869634. 2021.1989768
37. Padre A, Mourão LC. Correlation of Covid-19 With Stomatognathic System With Homeopathic Proposal for Adjunct Treatment to Increase Oral and General Health. Altern Ther Health Med 2020; 26 (S2): 112–6. https://pubmed.ncbi.nlm.nih.gov/33245703/
38. Emodi-Perlman A, Eli I, Smardz J et al. Temporomandibular Disorders and Bruxism Outbreak as a Possible Factor of Orofacial Pain Worsening during the COVID-19 Pandemic-Concomitant Research in Two Countries. J Clin Med 2020; 9 (10): 3250. DOI: 10.3390/jcm9103250
39. Peixoto KO, Resende CMBM, Almeida EO et al. Association of sleep quality and psychological aspects with reports of bruxism and TMD in Brazilian dentists during the COVID-19 pandemic. J Appl Oral Sci 2021; 29: e20201089. DOI: 10.1590/1678-7757-2020-1089
40. Zubair AS, McAlpine LS, Gardin T et al. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol 2020; 77 (8): 1018–27. DOI: 10.1001/jamaneurol.2020.2065
41. Sampaio Rocha-Filho PA, Voss L. Persistent Headache and Persistent Anosmia Associated With COVID-19. Headache 2020; 60 (8): 1797–9. DOI: 10.1111/head.13941
42. Tolebeyan AS, Zhang N, Cooper V, Kuruvilla DE. Headache in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Narrative Review. Headache 2020; 60 (10): 2131–38. DOI: 10.1111/head.13980
43. Medeiros KS, Macêdo LTA, Souza WF et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: a scoping review. Rev Assoc Med Bras (1992). 2021; 67 (2): 318–34. DOI: 10.1590/1806-9282.67.2.20200716
44. Brandini DA, Takamiya AS, Thakkar P et al. COVID-19 and oral diseases: Crosstalk, synergy or association? Rev Med Virol 2021; 31 (6): e2226. DOI: 10.1002/rmv.2226
45. Iranmanesh B, Khalili M, Amiri R et al. Oral manifestations of COVID-19 disease: A review article. Dermatol Ther 2021; 34 (1): e14578. DOI: 10.1111/dth.14578
46. Fakhruddin KS, Samaranayake LP, Buranawat B, Ngo H. Oro-facial mucocutaneous manifestations of Coronavirus Disease-2019 (COVID-19): A systematic review. PLoS One 2022; 17(6): e0265531. DOI: 10.1371/journal.pone.0265531
47. Gherlone EF, Polizzi E, Tetè G et al. Frequent and Persistent Salivary Gland Ectasia and Oral Disease After COVID-19. J Dent Res 2021; 100(5): 464–71. DOI: 10.1177/0022034521997112
48. Halboub E, Al-Maweri SA, Alanazi RH et al. Orofacial manifestations of COVID-19: a brief review of the published literature. Braz Oral Res 2020; 34: e124. DOI: 10.1590/1807-3107bor-2020.vol34.0124
49. Mehta R, Nagarkar NM, Ksbs KS et al. Facial Nerve Palsy in COVID-19-Associated Mucormycosis Patients: A Case Series. Cureus 2021; 13 (11): e19208. DOI: 10.7759/cureus.19208
50. Molaei H, Shojaeefar E, Nemati E et al. Iranian patients co-infected with COVID-19 and mucormycosis: the most common predisposing factor, clinical outcomes, laboratory markers and diagnosis, and drug therapies. Infect Dis (Lond) 2022: 1–14. DOI: 10.1080/23744235. 2022.2058604
51. Watanabe A, So M, Mitaka H et al. Clinical Features and Mortality of COVID-19-Associated Mucormycosis: A Systematic Review and Meta-Analysis. Mycopathologia 2022; 187 (2–3): 271–89. DOI: 10.1007/s11046-022-00627-8
52. Patel R, Jethva J, Bhagat PR et al. Rhino-orbital-cerebral mucormycosis: An epidemiological study from a tertiary care referral center in Western India. Indian J Ophthalmol 2022; 70–(4): 1371–5. DOI: 10.4103/ijo.IJO_2943_21
53. Hussain S, Baxi H, Riad A et al. COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. Int J Environ Res Public Health 2021; 18 (19): 10340. DOI: 10.3390/ijerph181910340
54. Jain K, Surana A, Choudhary TS et al. Clinical and histology features as predictor of severity of mucormycosis in post-COVID-19 patients: An experience from a rural tertiary setting in Central India. SAGE Open Med 2022; 10: 20503121221074785. DOI: 10.1177/ 20503121221074785
55. Wasiq M, Gn A. Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India. J Assoc Physicians India 2022; 70 (4): 11–2. URL: https://pubmed.ncbi. nlm.nih.gov/35443518/
56. Desai EJ, Pandya A, Upadhya I et al. Epidemiology, Clinical Features and Management of Rhino Orbital Mucormycosis in Post COVID 19 Patients. Indian J Otolaryngol Head Neck Surg 2022; 74 (1): 103–7. DOI: 10.1007/s12070-021-02807-2
57. Ramphul K, Verma R, Kumar N et al. Rising concerns of Mucormycosis (Zygomycosis) among COVID-19 patients; an analysis and review based on case reports in literature. Acta Biomed 2021; 92 (4): e2021271. DOI: 10.23750/abm.v92i4.11787
58. Gupta S, Ahuja P. Risk Factors for Procurence of Mucormycosis and its Manifestations Post Covid-19: a Single Arm Retrospective Unicentric Clinical Study. Indian J Otolaryngol Head Neck Surg 2021; Sep 18: 1–8. DOI: 10.1007/s12070-021-02825-0
59. Exposto FG, Castrillon EE, Exposto CR et al. Remote physical examination for temporomandibular disorders. Pain 2022; 163 (5): 936–42. DOI: 10.1097/j.pain.0000000000002455
60. Bavarian R, Pharr CA, Handa S et al. The utility of telemedicine in orofacial pain: Guidelines for examination and a retrospective review at a hospital-based practice. J Oral Rehabil 2022. DOI: 10.1111/joor.13335
61. Lee YH. Supportive Home Remedies for Orofacial Pain during the Coronavirus Disease 2019 Pandemic: Their Value and Limitations. Int J Dent 2022: 2005935. DOI: 10.1155/2022/2005935.
62. Dar-Odeh N, Elsayed S, Babkair H et al. What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review. J Dent Sci 2021; 16 (3): 806–16. DOI: 10.1016/j.jds.2020.11.007
63. Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123 (2): 114–21. DOI: 10.1111/bcpt.13023
64. Трухан Д.И., Коншу Н.В. Рациональная фармакотерапия в клинике внутренних болезней сквозь призму мультиморбидности и лекарственной безопасности. Справочник поликлинического врача. 2019; 2: 10–8. URL: https://www.elibrary.ru/ item.asp?id= 44162870
[Trukhan D.I., Konshu N.V. Ratsional'naia farmakoterapiia v klinike vnutrennikh boleznei skvoz' prizmu mul'timorbidnosti i lekarstvennoi bezopasnosti. Spravochnik poliklinicheskogo vracha. 2019; 2: 10–8. URL: https://www.elibrary.ru/item.asp?id=44162870 (in Russian).]
65. Zirk-Sadowski J, Masoli JA, Delgado J et. al. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (7): 1332–8. DOI: 10.1111/jgs.15385
66. Ble A, Zirk-Sadowski J, Masoli JA. Reply to: Proton Pump Inhibitors and Long-term Risk of Community-acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (12): 2428–9. DOI: 10.1111/jgs.15637
67. Yuan J, He O, Nguyen LH et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut 2020 Sep 28; gutjnl-2020-322557. DOI: 10.1136/gutjnl-2020-322557
68. Schubert ML. Adverse effects of proton pump inhibitors: fact or fake news? Curr Opin Gastroenterol 2018; 34 (6): 451–7. DOI: 10.1097/ MOG.0000000000000471
69. Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One 2019; 14 (5): e0216750. DOI: 10.1371/ journal.pone.0216750
70. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896–904. DOI: 10.1053/j.gastro.2009.11.014
71. Ngamruengphong S, Leontiadis GI, Radhi S et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011; 106: 1209–18. DOI: 10.1038/ajg.2011.113
72. Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019; 9 (1): 2282. DOI: 10.1038/s41598-019-39335-7
73. Bavishi C, Dupont HL. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34: 1269–81. DOI: 10.1111/j.1365-2036.2011.04874.x
74. Eom CS, Jeon CY, Lim JW et al. Use of acid-suppressive drugs and risk of pneumonia: A systematic review and meta-analysis. CMAJ 2011; 183: 310–9. DOI: 10.1503/cmaj.092129
75. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: Proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 1165–77. DOI: 10.1111/j.1365-2036.2010.04284.x
76. Zhou M, Zhang J, Liu J et al; CCC-ACS Investigators. Proton Pump Inhibitors and In-Hospital Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy. Mayo Clin Proc 2022 Feb 12: S0025-6196(21)00919-8. DOI: 10.1016/j.mayocp.2021.11.037
77. Charpiat B, Bleyzac N, Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? Clin Drug Investig 2020; 40 (10): 897–9. DOI: 10.1007/s40261-020-00963-x
78. Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol 2020; 115 (10): 1707–15. DOI: 10.14309/ajg.0000000000000798
79. Li GF, An XX, Yu Y et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut 2021; 70: 1806–8. DOI: 10.1136/gutjnl-2020-323366
80. Israelsen SB, Ernst MT, Lundh A et al. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis. Clin Gastroenterol Hepatol 2021; 19 (9): 1845–54.e6. DOI: 10.1016/j.cgh.2021.05.011
81. Toubasi AA, AbuAnzeh RB, Khraisat BR et al. Proton Pump Inhibitors: Current Use and the Risk of Coronavirus Infectious Disease 2019 Development and its Related Mortality. Meta-analysis. Arch Med Res 2021; 52 (6): 656–9. DOI: 10.1016/j.arcmed.2021.03.004
82. Yan C, Chen Y, Sun C et al. Does Proton Pump Inhibitor Use Lead to a Higher Risk of Coronavirus Disease 2019 Infection and Progression to Severe Disease? a Meta-analysis. Jpn J Infect Dis 2022; 75 (1): 10–15. DOI: 10.7883/yoken.JJID.2021.074
83. Kamal F, Khan MA, Sharma S et al. Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies. Gastroenterology 2021; 160 (7): 2588-2590.e7. DOI: 10.1053/j.gastro.2021.02.028
84. Kim HB, Kim JH, Wolf BJ. Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis. Eur J Clin Pharmacol 2022; 78 (3): 383–91. DOI: 10.1007/s00228-021-03255-1
85. Pranata R, Huang I, Lawrensia S et al. Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis. Pharmacol Rep 2021; 73 (6): 1642–9. DOI: 10.1007/s43440-021-00263-x
86. Ramachandran P, Perisetti A, Gajendran M et al. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19. Eur J Gastroenterol Hepatol 2022; 34 (2): 137–41. DOI: 10.1097/MEG. 0000000000002013
87. Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Эпителий-протективная терапия при коморбидных заболеваниях. Практические рекомендации для врачей. Терапевтический архив. 2022; 94 (8): 6–22. DOI: 10.26442/00403660.2022.08.201523
[Simanenkov V.I., Maev I.V., Tkacheva O.N. et al. Epitelii-protektivnaia terapiia pri komorbidnykh zabolevaniiakh. Prakticheskie rekomendatsii dlia vrachei. Terapevticheskii arkhiv. 2022; 94 (8): 6–22. DOI: 10.26442/00403660.2022.08.201523 (in Russian).]
88. Трухан Д.И. Рациональная фармакотерапия в реальной клинической практике сквозь призму мультиморбидности и лекарственной безопасности. Клинический разбор в общей медицине. 2020; 2: 29–39. DOI: 10.47407/kr2020.1.2.00015
[Trukhan D.I. Ratsional'naia farmakoterapiia v real'noi klinicheskoi praktike skvoz' prizmu mul'timorbidnosti i lekarstvennoi bezopasnosti. Klinicheskii razbor v obshchei meditsine. 2020; 2: 29–39. DOI: 10.47407/kr2020.1.2.00015 (in Russian).]
89. Трухан Д.И., Иванова Д.С. Роль и место синдрома повышенной эпителиальной проницаемости в развитии сердечно-сосудистых и бронхолегочных заболеваний: теоретические и практические аспекты применения ребамипида. Фарматека. 2021; 28 (5): 115–26. DOI: 10.18565/pharmateca.2021.5.115-126
[Trukhan D.I., Ivanova D.S. Rol' i mesto sindroma povyshennoi epitelial'noi pronitsaemosti v razvitii serdechno-sosudistykh i bronkholegochnykh zabolevanii: teoreticheskie i prakticheskie aspekty primeneniia rebamipida. Farmateka. 2021; 28 (5): 115–26. DOI: 10.18565/pharmateca.2021.5.115-126 (in Russian).]
90. Трухан Д.И., Иванова Д.С. Лекарственная безопасность в реальной клинической практике: акцент на протекторную терапию. Фарматека. 2022; 3: 72–82. DOI: 10.18565/pharmateca.2022.3.72-82
[Trukhan D.I., Ivanova D.S. Lekarstvennaia bezopasnost' v real'noi klinicheskoi praktike: aktsent na protektornuiu terapiiu. Farmateka. 2022; 3: 72–82. DOI: 10.18565/pharmateca.2022.3.72-82 (in Russian).]
91. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 2010; 4 (3): 261–70. DOI: 10.1586/ egh.10.25
92. Genta RM. Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther 2003; 18 (Suppl. 1): 8–13. DOI: 10.1046/j.1365-2036.18.s1.5.x
93. Yang BR, Lee JY, Kim MG. The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: An analysis of the national pharmacovigilance database in South Korea. J Dig Dis 2022; 23 (2): 118–23. DOI: 10.1111/1751-2980.13075
94. Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630
[Grinevich V.B., Gubonina I.V., Doshchitsin V.L. et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630 (in Russian).]
95. Wen X, Chen X, Zhou X. Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009; 34 (5): 457–60. URL: https://pubmed.ncbi.nlm.nih.gov/19483297/
96. Yasuda T, Chiba H, Satomi T et al. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res 2012; 2 (4): e3. DOI: 10.5037/jomr.2011.2403
97. Akagi S, Fujiwara T, Nishida M et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapyinduced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci 2019; 5: 16. DOI: 10.1186/s40780-019-0146-2
98. Urita Y, Watanabe T, Maeda T et al. Rebamipide and mosapride enhance pilocarpine-induced salivation. N Am J Med Sci 2009; 1 (3): 121–4. URL: https://pubmed.ncbi.nlm.nih.gov/22666683/
99. Гриневич В.Б., Кравчук Ю.А., Ткаченко Е.И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19. Экспериментальная и клиническая гастроэнтерология. 2020; 176 (4): 3–18. DOI: 10.31146/1682-8658-ecg-176-4-3-18
[Grinevich V.B., Kravchuk Iu.A., Tkachenko E.I. et al. Features of management of patients with gastroenterological pathology in the conditions of the COVID-19 pandemic. Experimental and Clinical Gastroenterology. 2020; 176 (4): 3–18. DOI: 10.31146/1682-8658-ecg-176-4-3-18 (in Russian).]
100. Ткачева О.Н., Котовская Ю.В, Алексанян Л. А. и др. Согласованная позиция экспертов Российской ассоциации геронтологов и гериатров. Новая коронавирусная инфекция SARS-CoV-2 (COVID19) у пациентов пожилого и старческого возраста: особенности профилактики, диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2020; 19 (3): 2601. DOI: 10.15829/1728-8800-2020-2601
[Tkacheva O.N., Kotovskaya Yu.V., Aleksanyan L.A et al. Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Cardiovascular Therapy and Prevention. 2020; 19 (3): 2601. DOI: 10.15829/1728-8800-2020-2601 (in Russian).]
101. Особенности течения Long-COVID инфекции. Терапевтические и реабилитационные мероприятия. Методические рекомендации (утверждены на ХVI Национальном Конгрессе терапевтов 18.11.2021). URL: https://www.rnmot.ru/ru/library/clinical
[Osobennosti techeniia Long-COVID infektsii. Terapevticheskie i reabilitatsionnye meropriiatiia. Metodicheskie rekomendatsii (utverzhdeny na KhVI Natsional'nom Kongresse terapevtov 18.11.2021). URL: https://www.rnmot.ru/ru/library/clinical (in Russian).]
102. Дробижев М.Ю. Сульпирид: механизм действия и возможности клинического использования. Психиатрия и психофармакотерапия. 2004; 4: 173–9. URL: https://www.elibrary.ru/ item.asp?id=26702734
[Drobizhev M.Iu. Sul'pirid: mekhanizm deistviia i vozmozhnosti klinicheskogo ispol'zovaniia. Psikhiatriia i psikhofarmakoterapiia. 2004; 4: 173–9. URL: https://www.elibrary.ru/item.asp? id=26702734 (in Russian).]
103. Данилов Д.С. Атипичный нейролептик сульпирид: спектр эффектов и возможности использования в клинической практике. Психиатрия и психофармакотерапия. 2011; 4: 19–27. URL: https://www.elibrary.ru/item.asp?id=16861398
[Danilov D.S. Atipichnyi neiroleptik sul'pirid: spektr effektov i vozmozhnosti ispol'zovaniia v klinicheskoi praktike. Psikhiatriia i psikhofarmakoterapiia. 2011; 4: 19–27. URL: https://www.elibrary.ru/item.asp?id=16861398 (in Russian).]
104. Данилов Д.С. Возможности использования сульпирида для лечения психических расстройств. Журнал неврологии и психиатрии им. C.C. Корсакова. 2012; 6: 91–8. URL: https://www.elibrary.ru/item.asp?id=17912115
[Danilov D.S. Vozmozhnosti ispol'zovaniia sul'pirida dlia lecheniia psikhicheskikh rasstroistv. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2012; 6: 91–8. URL: https://www.elibrary.ru/ item.asp?id=17912115 (in Russian).]
105. Данилов Д.С. Полувековой опыт использования нейролептиков-бензамидов в психиатрии и соматической медицине (на примере сульпирида). Человек и Лекарство – Казахстан. 2015; 8 (54): 106–15. URL: https://www.elibrary.ru/item.asp? id=24069895
[Danilov D.S. Poluvekovoi opyt ispol'zovaniia neiroleptikov-benzamidov v psikhiatrii i somaticheskoi meditsine (na primere sul'pirida). Chelovek i Lekarstvo – Kazakhstan. 2015; 8 (54): 106–15. URL: https://www.elibrary.ru/item.asp?id=24069895 (in Russian).]
106. Трухан Д.И., Тарасова Л.В. Клиника, диагностика и лечение хронического дуоденита. Экспериментальная и клиническая гастроэнтерология. 2012; 11: 104–14. URL: https://www.elibrary.ru/item.asp?id=21589957
[Trukhan D.I., Tarasova L.V. Klinika, diagnostika i lechenie khronicheskogo duodenita. Eksperimental'naia i klinicheskaia gastroenterologiia. 2012; 11: 104–14. URL: https://www.elibrary.ru/ item.asp?id=21589957 (in Russian).]
107. Трухан Д.И. Тревожно-депрессивные расстройства у гастроэнтерологических пациентов в амбулаторно-поликлинической практике. Фармация и фармакология. 2015; S1: 116–7. URL: https://www.elibrary.ru/item.asp?id=25220383
[Trukhan D.I. Trevozhno-depressivnye rasstroistva u gastroenterologicheskikh patsientov v ambulatorno-poliklinicheskoi praktike. Farmatsiia i farmakologiia. 2015; S1: 116–7. URL: https://www.elibrary.ru/item.asp?id=25220383 (in Russian).]
[Mezhdunarodnaia klassifikatsiia orofatsial'noi boli, 1-e izdanie (ICOP). Adaptirovannaia russkoiazychnaia versiia. Al'manakh klinicheskoi meditsiny. 2022; S: 3–80. DOI: 10.18786/2072-0505-2022-50-005 (in Russian).]
2. Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630
[Grinevich V.B., Gubonina I.V., Doshchitsin V.L. et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630 (in Russian).]
3. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации Минздрава России. 15-я версия от 22.02.2022 г. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/ 392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf
[Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Vremennye metodicheskie rekomendatsii Minzdrava Rossii. 15-ia versiia ot 22.02.2022 g. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/VMR_COVID-19_V15.pdf (in Russian).]
4. Casillas Santana MA, Arreguín Cano JA, Dib Kanán A et al. Should We Be Concerned about the Association of Diabetes Mellitus and Periodontal Disease in the Risk of Infection by SARS-CoV-2? A Systematic Review and Hypothesis. Medicina (Kaunas) 2021; 57 (5): 493. DOI: 10.3390/medicina57050493
5. Silvestre FJ, Márquez-Arrico CF. COVID-19 and Periodontitis: A Dangerous Association? Front Pharmacol 2022; 12: 789681. DOI: 10.3389/fphar.2021.789681
6. Jafer MA, Hazazi MA, Mashi MH et al. COVID-19 and Periodontitis: A Reality to Live with. J Contemp Dent Pract 2020; 21 (12): 1398–403. URL: https://pubmed.ncbi.nlm.nih.gov/33893266/#affiliation-1
7. Campisi G, Bizzoca ME, Lo Muzio L. COVID-19 and periodontitis: reflecting on a possible association. Head Face Med 2021; 17 (1): 16. DOI: 10.1186/s13005-021-00267-1
8. Kusiak A, Cichońska D, Tubaja M et al. COVID-19 manifestation in the oral cavity – a narrative literature review. Acta Otorhinolaryngol Ital 2021; 41 (5): 395–400. DOI: 10.14639/0392-100X-N1584
9. Basso L, Chacun D, Sy K et al. Periodontal Diseases and COVID-19: A Scoping Review. Eur J Dent 2021; 15 (4): 768–75. DOI: 10.1055/s-0041-1729139
10. Grigoriadis A, Räisänen IT, Pärnänen P et al. Is There a Link between COVID-19 and Periodontal Disease? A Narrative Review. Eur J Dent 2022. DOI: 10.1055/s-0041-1740223
11. Brock M, Bahammam S, Sima C. The Relationships Among Periodontitis, Pneumonia and COVID-19. Front Oral Health 2022; 2: 801815. DOI: 10.3389/froh.2021.801815
12. Qi X, Northridge ME, Hu M, Wu B. Oral health conditions and COVID-19: A systematic review and meta-analysis of the current evidence. Aging Health Res 2022; 2 (1): 100064. DOI: 10.1016/j.ahr.2022.100064
13. Biadsee A, Biadsee A, Kassem F et al. Olfactory and Oral Manifestations of COVID-19: Sex-Related Symptoms-A Potential Pathway to Early Diagnosis. Otolaryngol Head Neck Surg 2020; 163 (4): 722–8. DOI: 10.1177/0194599820934380
14. Dar-Odeh N, Bobamuratova DT, Alnazzawi A et al. Jaw-related complications in COVID-19 patients; a systematic review. Cranio 2022: 1–8. DOI: 10.1080/08869634.2022.2031438
15. Saccomanno S, Bernabei M, Scoppa F et al. Coronavirus Lockdown as a Major Life Stressor: Does It Affect TMD Symptoms? Int J Environ Res Public Health 2020; 17 (23): 8907. DOI: 10.3390/ijerph17238907
16. Manfredini D, Marini M, Pavan C et al. Psychosocial profiles of painful TMD patients. J Oral Rehabil 2009; 36 (3): 193–8. DOI: 10.1111/j.1365-2842.2008.01926.x
17. Manfredini D, Lombardo L, Siciliani G. Temporomandibular disorders and dental occlusion. A systematic review of association studies: end of an era? J Oral Rehabil 2017; 44 (11): 908–23. DOI: 10.1111/joor.12531
18. De La Torre Canales G, Câmara-Souza MB, Muñoz Lora VR et al. Prevalence of psychosocial impairment in temporomandibular disorder patients: a systematic review. J Oral Rehabil 2018; 45 (11): 881–9. DOI: 10.1111/joor.12685
19. Kindler S, Samietz S, Houshmand M et al. Depressive and anxiety symptoms as risk factors for temporomandibular joint pain: a prospective cohort study in the general population. J Pain 2012; 13 (12): 1188–97. DOI: 10.1016/j.jpain.2012.09.004
20. Boscato N, Almeida RC, Koller CD et al. Influence of anxiety on temporomandibular disorders: an epidemiological survey with elders and adults in Southern Brazil. J Oral Rehabil 2013; 40 (9): 643–9. DOI: 10.1111/joor.12076
21. Osiewicz M, Lobbezoo F, Ciapała B et al. Pain predictors in a population of temporomandibular disorders patients. J Clin Med 2020; 9 (2): 452. DOI: 10.3390/jcm9020452
22. Almeida-Leite CM, Stuginski-Barbosa J, Conti PCR. How psychosocial and economic impacts of COVID-19 pandemic can interfere on bruxism and temporomandibular disorders? J Appl Oral Sci 2020; 28: e20200263. DOI: 10.1590/1678-7757-2020-0263
23. Quadri MF, Mahnashi A, Al Almutahhir A et al. Association of awake bruxism with khat, coffee, tobacco, and stress among Jazan University Students. Int J Dent 2015; 2015: 842096. DOI: 10.1155/ 2015/842096
24. Smardz J, Martynowicz H, Wojakowska A et al. Correlation between sleep bruxism, stress, and depression-A polysomnographic study. J Clin Med 2019; 8 (9): 1344. DOI: 10.3390/jcm8091344
25. Smardz J, Martynowicz H, Michalek-Zrabkowska M et al. Sleep bruxism and occurrence of temporomandibular disorders-related pain: a polysomnographic study. Front Neurol 2019; 10: 168. DOI: 10.3389/ fneur.2019.0016
26. Polmann H, Domingos FL, Melo G et al. Association between sleep bruxism and anxiety symptoms in adults: a systematic review. J Oral Rehabil 2019; 46 (5): 482 91. DOI: 10.1111/joor.12785
27. Przystańska A, Jasielska A, Ziarko M et al. Psychosocial predictors of bruxism. Biomed Res Int 2019; 2019: 2069716. DOI: 10.1155/2019/2069716
28. Wieckiewicz M, Smardz J, Martynowicz H et al. Distribution of temporomandibular disorders among sleep bruxers and non-bruxers: a polysomnographic study. J Oral Rehabil 2020; 10.1111/joor.12955. DOI: 10.1111/joor.1295
29. Saccomanno S, Bernabei M, Scoppa F et al. Coronavirus Lockdown as a Major Life Stressor: Does It Affect TMD Symptoms? Int J Environ Res Public Health 2020; 17 (23): 8907. DOI: 10.3390/ijerph17238907
30. Machoň V, Levorová J, Beňo M, Foltán R. The Manifestations of Covid-19 Infection. Manifestations in Patients with Temporomandibular Joint Disorders. Prague Med Rep 2022; 123 (2): 95–100. DOI: 10.14712/23362936.2022.10
31. DE Caxias FP, Athayde FRF, Januzzi MS et al. Impact event and orofacial pain amid the COVID-19 pandemic in Brazil: a cross-sectional epidemiological study. J Appl Oral Sci 2021; 29: e20210122. DOI: 10.1590/1678-7757-2021-0122
32. Badrah M, Riad A, Kassem I et al. Craniofacial pain in COVID-19 patients with diabetes mellitus: Clinical and laboratory description of 21 cases. J Med Virol 2021; 93 (5): 2616–9. DOI: 10.1002/jmv.26866
33. Asquini G, Bianchi AE, Borromeo G et al. The impact of COVID-19-related distress on general health, oral behaviour, psychosocial features, disability and pain intensity in a cohort of Italian patients with temporomandibular disorders. PLoS One 2021; 16 (2): e0245999. DOI: 10.1371/journal.pone.0245999
34. Saki M, Shadmanpour M, Najafi HZ. Are individuals with orofacial pain more prone to psychological distress during the COVID-19 pandemic? Dent Med Probl 2021; 58 (1): 17–25. DOI: 10.17219/dmp/ 131683
35. Emodi-Perlman A, Eli I. One year into the COVID-19 pandemic – temporomandibular disorders and bruxism: What we have learned and what we can do to improve our manner of treatment. Dent Med Probl 2021; 58 (2): 215–8. DOI: 10.17219/dmp/132896
36. Colonna A, Guarda-Nardini L, Ferrari M, Manfredini D. COVID-19 pandemic and the psyche, bruxism, temporomandibular disorders triangle. Cranio 2021; Oct 15: 1–6. DOI: 10.1080/08869634. 2021.1989768
37. Padre A, Mourão LC. Correlation of Covid-19 With Stomatognathic System With Homeopathic Proposal for Adjunct Treatment to Increase Oral and General Health. Altern Ther Health Med 2020; 26 (S2): 112–6. https://pubmed.ncbi.nlm.nih.gov/33245703/
38. Emodi-Perlman A, Eli I, Smardz J et al. Temporomandibular Disorders and Bruxism Outbreak as a Possible Factor of Orofacial Pain Worsening during the COVID-19 Pandemic-Concomitant Research in Two Countries. J Clin Med 2020; 9 (10): 3250. DOI: 10.3390/jcm9103250
39. Peixoto KO, Resende CMBM, Almeida EO et al. Association of sleep quality and psychological aspects with reports of bruxism and TMD in Brazilian dentists during the COVID-19 pandemic. J Appl Oral Sci 2021; 29: e20201089. DOI: 10.1590/1678-7757-2020-1089
40. Zubair AS, McAlpine LS, Gardin T et al. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol 2020; 77 (8): 1018–27. DOI: 10.1001/jamaneurol.2020.2065
41. Sampaio Rocha-Filho PA, Voss L. Persistent Headache and Persistent Anosmia Associated With COVID-19. Headache 2020; 60 (8): 1797–9. DOI: 10.1111/head.13941
42. Tolebeyan AS, Zhang N, Cooper V, Kuruvilla DE. Headache in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Narrative Review. Headache 2020; 60 (10): 2131–38. DOI: 10.1111/head.13980
43. Medeiros KS, Macêdo LTA, Souza WF et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: a scoping review. Rev Assoc Med Bras (1992). 2021; 67 (2): 318–34. DOI: 10.1590/1806-9282.67.2.20200716
44. Brandini DA, Takamiya AS, Thakkar P et al. COVID-19 and oral diseases: Crosstalk, synergy or association? Rev Med Virol 2021; 31 (6): e2226. DOI: 10.1002/rmv.2226
45. Iranmanesh B, Khalili M, Amiri R et al. Oral manifestations of COVID-19 disease: A review article. Dermatol Ther 2021; 34 (1): e14578. DOI: 10.1111/dth.14578
46. Fakhruddin KS, Samaranayake LP, Buranawat B, Ngo H. Oro-facial mucocutaneous manifestations of Coronavirus Disease-2019 (COVID-19): A systematic review. PLoS One 2022; 17(6): e0265531. DOI: 10.1371/journal.pone.0265531
47. Gherlone EF, Polizzi E, Tetè G et al. Frequent and Persistent Salivary Gland Ectasia and Oral Disease After COVID-19. J Dent Res 2021; 100(5): 464–71. DOI: 10.1177/0022034521997112
48. Halboub E, Al-Maweri SA, Alanazi RH et al. Orofacial manifestations of COVID-19: a brief review of the published literature. Braz Oral Res 2020; 34: e124. DOI: 10.1590/1807-3107bor-2020.vol34.0124
49. Mehta R, Nagarkar NM, Ksbs KS et al. Facial Nerve Palsy in COVID-19-Associated Mucormycosis Patients: A Case Series. Cureus 2021; 13 (11): e19208. DOI: 10.7759/cureus.19208
50. Molaei H, Shojaeefar E, Nemati E et al. Iranian patients co-infected with COVID-19 and mucormycosis: the most common predisposing factor, clinical outcomes, laboratory markers and diagnosis, and drug therapies. Infect Dis (Lond) 2022: 1–14. DOI: 10.1080/23744235. 2022.2058604
51. Watanabe A, So M, Mitaka H et al. Clinical Features and Mortality of COVID-19-Associated Mucormycosis: A Systematic Review and Meta-Analysis. Mycopathologia 2022; 187 (2–3): 271–89. DOI: 10.1007/s11046-022-00627-8
52. Patel R, Jethva J, Bhagat PR et al. Rhino-orbital-cerebral mucormycosis: An epidemiological study from a tertiary care referral center in Western India. Indian J Ophthalmol 2022; 70–(4): 1371–5. DOI: 10.4103/ijo.IJO_2943_21
53. Hussain S, Baxi H, Riad A et al. COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. Int J Environ Res Public Health 2021; 18 (19): 10340. DOI: 10.3390/ijerph181910340
54. Jain K, Surana A, Choudhary TS et al. Clinical and histology features as predictor of severity of mucormycosis in post-COVID-19 patients: An experience from a rural tertiary setting in Central India. SAGE Open Med 2022; 10: 20503121221074785. DOI: 10.1177/ 20503121221074785
55. Wasiq M, Gn A. Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India. J Assoc Physicians India 2022; 70 (4): 11–2. URL: https://pubmed.ncbi. nlm.nih.gov/35443518/
56. Desai EJ, Pandya A, Upadhya I et al. Epidemiology, Clinical Features and Management of Rhino Orbital Mucormycosis in Post COVID 19 Patients. Indian J Otolaryngol Head Neck Surg 2022; 74 (1): 103–7. DOI: 10.1007/s12070-021-02807-2
57. Ramphul K, Verma R, Kumar N et al. Rising concerns of Mucormycosis (Zygomycosis) among COVID-19 patients; an analysis and review based on case reports in literature. Acta Biomed 2021; 92 (4): e2021271. DOI: 10.23750/abm.v92i4.11787
58. Gupta S, Ahuja P. Risk Factors for Procurence of Mucormycosis and its Manifestations Post Covid-19: a Single Arm Retrospective Unicentric Clinical Study. Indian J Otolaryngol Head Neck Surg 2021; Sep 18: 1–8. DOI: 10.1007/s12070-021-02825-0
59. Exposto FG, Castrillon EE, Exposto CR et al. Remote physical examination for temporomandibular disorders. Pain 2022; 163 (5): 936–42. DOI: 10.1097/j.pain.0000000000002455
60. Bavarian R, Pharr CA, Handa S et al. The utility of telemedicine in orofacial pain: Guidelines for examination and a retrospective review at a hospital-based practice. J Oral Rehabil 2022. DOI: 10.1111/joor.13335
61. Lee YH. Supportive Home Remedies for Orofacial Pain during the Coronavirus Disease 2019 Pandemic: Their Value and Limitations. Int J Dent 2022: 2005935. DOI: 10.1155/2022/2005935.
62. Dar-Odeh N, Elsayed S, Babkair H et al. What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review. J Dent Sci 2021; 16 (3): 806–16. DOI: 10.1016/j.jds.2020.11.007
63. Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123 (2): 114–21. DOI: 10.1111/bcpt.13023
64. Трухан Д.И., Коншу Н.В. Рациональная фармакотерапия в клинике внутренних болезней сквозь призму мультиморбидности и лекарственной безопасности. Справочник поликлинического врача. 2019; 2: 10–8. URL: https://www.elibrary.ru/ item.asp?id= 44162870
[Trukhan D.I., Konshu N.V. Ratsional'naia farmakoterapiia v klinike vnutrennikh boleznei skvoz' prizmu mul'timorbidnosti i lekarstvennoi bezopasnosti. Spravochnik poliklinicheskogo vracha. 2019; 2: 10–8. URL: https://www.elibrary.ru/item.asp?id=44162870 (in Russian).]
65. Zirk-Sadowski J, Masoli JA, Delgado J et. al. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (7): 1332–8. DOI: 10.1111/jgs.15385
66. Ble A, Zirk-Sadowski J, Masoli JA. Reply to: Proton Pump Inhibitors and Long-term Risk of Community-acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (12): 2428–9. DOI: 10.1111/jgs.15637
67. Yuan J, He O, Nguyen LH et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut 2020 Sep 28; gutjnl-2020-322557. DOI: 10.1136/gutjnl-2020-322557
68. Schubert ML. Adverse effects of proton pump inhibitors: fact or fake news? Curr Opin Gastroenterol 2018; 34 (6): 451–7. DOI: 10.1097/ MOG.0000000000000471
69. Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One 2019; 14 (5): e0216750. DOI: 10.1371/ journal.pone.0216750
70. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896–904. DOI: 10.1053/j.gastro.2009.11.014
71. Ngamruengphong S, Leontiadis GI, Radhi S et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011; 106: 1209–18. DOI: 10.1038/ajg.2011.113
72. Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019; 9 (1): 2282. DOI: 10.1038/s41598-019-39335-7
73. Bavishi C, Dupont HL. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34: 1269–81. DOI: 10.1111/j.1365-2036.2011.04874.x
74. Eom CS, Jeon CY, Lim JW et al. Use of acid-suppressive drugs and risk of pneumonia: A systematic review and meta-analysis. CMAJ 2011; 183: 310–9. DOI: 10.1503/cmaj.092129
75. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: Proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 1165–77. DOI: 10.1111/j.1365-2036.2010.04284.x
76. Zhou M, Zhang J, Liu J et al; CCC-ACS Investigators. Proton Pump Inhibitors and In-Hospital Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy. Mayo Clin Proc 2022 Feb 12: S0025-6196(21)00919-8. DOI: 10.1016/j.mayocp.2021.11.037
77. Charpiat B, Bleyzac N, Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? Clin Drug Investig 2020; 40 (10): 897–9. DOI: 10.1007/s40261-020-00963-x
78. Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol 2020; 115 (10): 1707–15. DOI: 10.14309/ajg.0000000000000798
79. Li GF, An XX, Yu Y et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut 2021; 70: 1806–8. DOI: 10.1136/gutjnl-2020-323366
80. Israelsen SB, Ernst MT, Lundh A et al. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis. Clin Gastroenterol Hepatol 2021; 19 (9): 1845–54.e6. DOI: 10.1016/j.cgh.2021.05.011
81. Toubasi AA, AbuAnzeh RB, Khraisat BR et al. Proton Pump Inhibitors: Current Use and the Risk of Coronavirus Infectious Disease 2019 Development and its Related Mortality. Meta-analysis. Arch Med Res 2021; 52 (6): 656–9. DOI: 10.1016/j.arcmed.2021.03.004
82. Yan C, Chen Y, Sun C et al. Does Proton Pump Inhibitor Use Lead to a Higher Risk of Coronavirus Disease 2019 Infection and Progression to Severe Disease? a Meta-analysis. Jpn J Infect Dis 2022; 75 (1): 10–15. DOI: 10.7883/yoken.JJID.2021.074
83. Kamal F, Khan MA, Sharma S et al. Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies. Gastroenterology 2021; 160 (7): 2588-2590.e7. DOI: 10.1053/j.gastro.2021.02.028
84. Kim HB, Kim JH, Wolf BJ. Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis. Eur J Clin Pharmacol 2022; 78 (3): 383–91. DOI: 10.1007/s00228-021-03255-1
85. Pranata R, Huang I, Lawrensia S et al. Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis. Pharmacol Rep 2021; 73 (6): 1642–9. DOI: 10.1007/s43440-021-00263-x
86. Ramachandran P, Perisetti A, Gajendran M et al. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19. Eur J Gastroenterol Hepatol 2022; 34 (2): 137–41. DOI: 10.1097/MEG. 0000000000002013
87. Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Эпителий-протективная терапия при коморбидных заболеваниях. Практические рекомендации для врачей. Терапевтический архив. 2022; 94 (8): 6–22. DOI: 10.26442/00403660.2022.08.201523
[Simanenkov V.I., Maev I.V., Tkacheva O.N. et al. Epitelii-protektivnaia terapiia pri komorbidnykh zabolevaniiakh. Prakticheskie rekomendatsii dlia vrachei. Terapevticheskii arkhiv. 2022; 94 (8): 6–22. DOI: 10.26442/00403660.2022.08.201523 (in Russian).]
88. Трухан Д.И. Рациональная фармакотерапия в реальной клинической практике сквозь призму мультиморбидности и лекарственной безопасности. Клинический разбор в общей медицине. 2020; 2: 29–39. DOI: 10.47407/kr2020.1.2.00015
[Trukhan D.I. Ratsional'naia farmakoterapiia v real'noi klinicheskoi praktike skvoz' prizmu mul'timorbidnosti i lekarstvennoi bezopasnosti. Klinicheskii razbor v obshchei meditsine. 2020; 2: 29–39. DOI: 10.47407/kr2020.1.2.00015 (in Russian).]
89. Трухан Д.И., Иванова Д.С. Роль и место синдрома повышенной эпителиальной проницаемости в развитии сердечно-сосудистых и бронхолегочных заболеваний: теоретические и практические аспекты применения ребамипида. Фарматека. 2021; 28 (5): 115–26. DOI: 10.18565/pharmateca.2021.5.115-126
[Trukhan D.I., Ivanova D.S. Rol' i mesto sindroma povyshennoi epitelial'noi pronitsaemosti v razvitii serdechno-sosudistykh i bronkholegochnykh zabolevanii: teoreticheskie i prakticheskie aspekty primeneniia rebamipida. Farmateka. 2021; 28 (5): 115–26. DOI: 10.18565/pharmateca.2021.5.115-126 (in Russian).]
90. Трухан Д.И., Иванова Д.С. Лекарственная безопасность в реальной клинической практике: акцент на протекторную терапию. Фарматека. 2022; 3: 72–82. DOI: 10.18565/pharmateca.2022.3.72-82
[Trukhan D.I., Ivanova D.S. Lekarstvennaia bezopasnost' v real'noi klinicheskoi praktike: aktsent na protektornuiu terapiiu. Farmateka. 2022; 3: 72–82. DOI: 10.18565/pharmateca.2022.3.72-82 (in Russian).]
91. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 2010; 4 (3): 261–70. DOI: 10.1586/ egh.10.25
92. Genta RM. Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther 2003; 18 (Suppl. 1): 8–13. DOI: 10.1046/j.1365-2036.18.s1.5.x
93. Yang BR, Lee JY, Kim MG. The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: An analysis of the national pharmacovigilance database in South Korea. J Dig Dis 2022; 23 (2): 118–23. DOI: 10.1111/1751-2980.13075
94. Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630
[Grinevich V.B., Gubonina I.V., Doshchitsin V.L. et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630 (in Russian).]
95. Wen X, Chen X, Zhou X. Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009; 34 (5): 457–60. URL: https://pubmed.ncbi.nlm.nih.gov/19483297/
96. Yasuda T, Chiba H, Satomi T et al. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res 2012; 2 (4): e3. DOI: 10.5037/jomr.2011.2403
97. Akagi S, Fujiwara T, Nishida M et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapyinduced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci 2019; 5: 16. DOI: 10.1186/s40780-019-0146-2
98. Urita Y, Watanabe T, Maeda T et al. Rebamipide and mosapride enhance pilocarpine-induced salivation. N Am J Med Sci 2009; 1 (3): 121–4. URL: https://pubmed.ncbi.nlm.nih.gov/22666683/
99. Гриневич В.Б., Кравчук Ю.А., Ткаченко Е.И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19. Экспериментальная и клиническая гастроэнтерология. 2020; 176 (4): 3–18. DOI: 10.31146/1682-8658-ecg-176-4-3-18
[Grinevich V.B., Kravchuk Iu.A., Tkachenko E.I. et al. Features of management of patients with gastroenterological pathology in the conditions of the COVID-19 pandemic. Experimental and Clinical Gastroenterology. 2020; 176 (4): 3–18. DOI: 10.31146/1682-8658-ecg-176-4-3-18 (in Russian).]
100. Ткачева О.Н., Котовская Ю.В, Алексанян Л. А. и др. Согласованная позиция экспертов Российской ассоциации геронтологов и гериатров. Новая коронавирусная инфекция SARS-CoV-2 (COVID19) у пациентов пожилого и старческого возраста: особенности профилактики, диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2020; 19 (3): 2601. DOI: 10.15829/1728-8800-2020-2601
[Tkacheva O.N., Kotovskaya Yu.V., Aleksanyan L.A et al. Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Cardiovascular Therapy and Prevention. 2020; 19 (3): 2601. DOI: 10.15829/1728-8800-2020-2601 (in Russian).]
101. Особенности течения Long-COVID инфекции. Терапевтические и реабилитационные мероприятия. Методические рекомендации (утверждены на ХVI Национальном Конгрессе терапевтов 18.11.2021). URL: https://www.rnmot.ru/ru/library/clinical
[Osobennosti techeniia Long-COVID infektsii. Terapevticheskie i reabilitatsionnye meropriiatiia. Metodicheskie rekomendatsii (utverzhdeny na KhVI Natsional'nom Kongresse terapevtov 18.11.2021). URL: https://www.rnmot.ru/ru/library/clinical (in Russian).]
102. Дробижев М.Ю. Сульпирид: механизм действия и возможности клинического использования. Психиатрия и психофармакотерапия. 2004; 4: 173–9. URL: https://www.elibrary.ru/ item.asp?id=26702734
[Drobizhev M.Iu. Sul'pirid: mekhanizm deistviia i vozmozhnosti klinicheskogo ispol'zovaniia. Psikhiatriia i psikhofarmakoterapiia. 2004; 4: 173–9. URL: https://www.elibrary.ru/item.asp? id=26702734 (in Russian).]
103. Данилов Д.С. Атипичный нейролептик сульпирид: спектр эффектов и возможности использования в клинической практике. Психиатрия и психофармакотерапия. 2011; 4: 19–27. URL: https://www.elibrary.ru/item.asp?id=16861398
[Danilov D.S. Atipichnyi neiroleptik sul'pirid: spektr effektov i vozmozhnosti ispol'zovaniia v klinicheskoi praktike. Psikhiatriia i psikhofarmakoterapiia. 2011; 4: 19–27. URL: https://www.elibrary.ru/item.asp?id=16861398 (in Russian).]
104. Данилов Д.С. Возможности использования сульпирида для лечения психических расстройств. Журнал неврологии и психиатрии им. C.C. Корсакова. 2012; 6: 91–8. URL: https://www.elibrary.ru/item.asp?id=17912115
[Danilov D.S. Vozmozhnosti ispol'zovaniia sul'pirida dlia lecheniia psikhicheskikh rasstroistv. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2012; 6: 91–8. URL: https://www.elibrary.ru/ item.asp?id=17912115 (in Russian).]
105. Данилов Д.С. Полувековой опыт использования нейролептиков-бензамидов в психиатрии и соматической медицине (на примере сульпирида). Человек и Лекарство – Казахстан. 2015; 8 (54): 106–15. URL: https://www.elibrary.ru/item.asp? id=24069895
[Danilov D.S. Poluvekovoi opyt ispol'zovaniia neiroleptikov-benzamidov v psikhiatrii i somaticheskoi meditsine (na primere sul'pirida). Chelovek i Lekarstvo – Kazakhstan. 2015; 8 (54): 106–15. URL: https://www.elibrary.ru/item.asp?id=24069895 (in Russian).]
106. Трухан Д.И., Тарасова Л.В. Клиника, диагностика и лечение хронического дуоденита. Экспериментальная и клиническая гастроэнтерология. 2012; 11: 104–14. URL: https://www.elibrary.ru/item.asp?id=21589957
[Trukhan D.I., Tarasova L.V. Klinika, diagnostika i lechenie khronicheskogo duodenita. Eksperimental'naia i klinicheskaia gastroenterologiia. 2012; 11: 104–14. URL: https://www.elibrary.ru/ item.asp?id=21589957 (in Russian).]
107. Трухан Д.И. Тревожно-депрессивные расстройства у гастроэнтерологических пациентов в амбулаторно-поликлинической практике. Фармация и фармакология. 2015; S1: 116–7. URL: https://www.elibrary.ru/item.asp?id=25220383
[Trukhan D.I. Trevozhno-depressivnye rasstroistva u gastroenterologicheskikh patsientov v ambulatorno-poliklinicheskoi praktike. Farmatsiia i farmakologiia. 2015; S1: 116–7. URL: https://www.elibrary.ru/item.asp?id=25220383 (in Russian).]
For citation:Trukhan D.I., Sulimov A.F., Trukhan L.Yu. et al. Orofacial pain during the new coronavirus infection (COVID-19) pandemic. Clinical review for general practice. 2022; 4: 54–65. DOI: 10.47407/kr2022.3.4.00153
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.